Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

Abstract Purpose Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ tria...

Full description

Bibliographic Details
Main Authors: Wei Sang, Ming Shi, Jingjing Yang, Jiang Cao, Linyan Xu, Dongmei Yan, Meixue Yao, Hui Liu, Weidong Li, Bing Zhang, Kemeng Sun, Xuguang Song, Cai Sun, Jun Jiao, Yuanyuan Qin, Tingting Sang, Yuanyuan Ma, Mei Wu, Xiang Gao, Hai Cheng, Zhiling Yan, Depeng Li, Haiying Sun, Feng Zhu, Ying Wang, Lingyu Zeng, Zhenyu Li, Junnian Zheng, Kailin Xu
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Cancer Medicine
Subjects:
CAR‐T
CD19
CD20
clinical trial
DLBCL
Online Access:https://doi.org/10.1002/cam4.3259

Internet

https://doi.org/10.1002/cam4.3259

Similar Items